Targeted therapy for HER2-negative breast cancer, ‘Ibrance’ acquires approval
Silent for more than ten years. a targeted therapy for Human Epidermal Growth Factor Receptor 2(HER2)-negative breast cancer acquired approval of commercialization in Korea.
On the 29th, the Ministry of Food and Drug Safety approved Pfizer’s Ibrance Cap 75, 100 & 125mg(generic name: palbociclib)...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
